Safety and Pharmacokinetics of Cemiplimab Anti-programmed Death-ligand 1 (Anti-PD-1) and Other Agents in Japanese Adult Patients With Advanced Malignancies
Clinical trial NCT03233139 · ACTIVE_NOT_RECRUITING
Trial details
- NCT number
- NCT03233139
- Sponsor
- Regeneron Pharmaceuticals
- Status
- ACTIVE_NOT_RECRUITING
- Phase
- Phase 1
- Study type
- INTERVENTIONAL
- Start date
- 2017-06-21
- Primary completion
- 2027-09-30
- Enrollment
- 146
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.